在新泽西州一种独特护理模式中用于治疗丙型肝炎感染的两种直接抗病毒药物的比较
A Comparison of Two DAAs Used in a Unique Model of Care to Treat Hepatitis C Infections in New Jersey.
作者信息
Slim Jihad, Bellafiore Paul, Tempalski Barbara, Rosmarin-DeStefano Corey, Leyden Kevin, Torres Juan, Duprey Sheena, Levaggi Emily
机构信息
NYMC, St. Michaels Medical Center, Newark, New Jersey, USA.
NJCRI, Newark, New Jersey, USA.
出版信息
Open Forum Infect Dis. 2024 Nov 27;11(12):ofae645. doi: 10.1093/ofid/ofae645. eCollection 2024 Dec.
In this prospective observational study, we compare the efficacy of glecaprevir/pibrentasvir vs sofosbuvir/velpatasvir in treating hepatitis C within a unique model of care utilizing a combination of telehealth, an ambulatory van, case management, and a contracted pharmacy. Among 769 patients treated, 90.4% completed treatment, with 9.6% lost to follow-up. Both regimens demonstrated high completion rates and efficacy.
在这项前瞻性观察性研究中，我们在一个独特的护理模式中比较了glecaprevir/pibrentasvir与sofosbuvir/velpatasvir治疗丙型肝炎的疗效，该护理模式结合了远程医疗、流动医疗车、病例管理和一家签约药房。在接受治疗的769例患者中，90.4%完成了治疗，9.6%失访。两种治疗方案均显示出高完成率和疗效。
Zotero 插件